NCT03367715View on ClinicalTrials.gov

Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

May 20, 2021

Study Completion Date

March 17, 2022

Conditions
MGMT-unmethylated Glioblastoma (GBM)GBM
Interventions
DRUG

Nivolumab

study treatment on Day 1 with one dose of nivolumab 3 mg/kg

DRUG

Ipilimumab

study treatment on Day 1 with one dose of ipilimumab 1mg/kg

RADIATION

Radiation Therapy (RT)

total dose of 30 Gy, given in 5 consecutive fractions of 6 Gy each fraction.

Trial Locations (1)

10016

New York University School of Medicine, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT03367715 - Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma | Biotech Hunter | Biotech Hunter